Our findings identify mitochondrial Cu as a central mediator of D-flow-induced atherosclerosis and highlight the CTR1/SLC25A3 axis as a promising therapeutic target to mitigate mitochondrial dysfunction, cuproptosis, and atherosclerosis. This evidence concerns the gene SLC25A3 and atherosclerosis.